scPharmaceuticals Inc (FRA:2SX)
€ 3.34 -0.12 (-3.47%) Market Cap: 176.08 Mil Enterprise Value: 139.10 Mil PE Ratio: 0 PB Ratio: 6.04 GF Score: 28/100

scPharmaceuticals Inc at Jefferies London Healthcare Conference Transcript

Nov 16, 2022 / 05:35PM GMT
Release Date Price: €6.2 (+1.64%)
Glen Santangelo
Jefferies - Analyst

Good afternoon, everybody. Why don't we get started. For those of you who don't know me, I'm Glen Santangelo on the new Spec Pharma Analyst at Jefferies. We recently launched on the space not too long ago.

And one of the companies we're very excited about is scPharmaceuticals, which we're happy that we have presenting here today. To my left is the President and CEO, John Tucker; and in the audience out there, we have John Morris, who heads clinical development and medical affairs, regulatory affairs, whatever. So, thank you for joining us, that's really awesome.

And it was this one of the stories we are really excited about. It's a company that recently got approval on an interesting drug device combination. And we don't think many investors are paying attention, which we think really presents a great opportunity for folks ahead, of what could be a pretty interesting launch in the first quarter of 2023.

So with that, why don't I turn it over to John. He has some slides to run through and maybe at the end, if we have a few minutes, I may

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot